お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:ヒト成長ホルモン(HGH)の世界市場 - 成長、動向、予測(2019年~2024年)
市場調査レポート
商品コード
659350

ヒト成長ホルモン(HGH)の世界市場 - 成長、動向、予測(2019年~2024年)

Human Growth Hormone (HGH) Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
ヒト成長ホルモン(HGH)の世界市場 - 成長、動向、予測(2019年~2024年)
出版日: 2021年03月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のヒト成長ホルモン(HGH)市場は、2014年から2024年にかけて6.8%のCAGRで推移すると予測されています。ソマトトロピンとも呼ばれるヒト成長ホルモンは、成長や細胞再生を刺激するペプチドホルモンです。成長ホルモンの用途の拡大や、低身長の治療薬としての認知度の高まりなどによって当市場の成長が促進されています。

当レポートでは、ヒト成長ホルモン(HGH)の世界市場を調査し、市場の概要、用途・流通チャネル・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 組み換え型ヒト成長ホルモン薬の開発
    • 下垂体機能障害症の増加
    • ヒト成長ホルモンの適用外使用の増加
  • 市場の阻害要因
    • ヒト成長ホルモンに関連する有害作用
    • 厳格な規制プロセス
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 用途別
    • 成長ホルモン欠乏症
    • ターナー症候群
    • 特発性低身長
    • プラダーウィリー症候群
    • その他
  • 流通チャネル別
    • 病院・小売薬局
    • オンライン薬局
    • 専門クリニック
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • AnkeBio Co. Ltd
    • EMD Serono Inc.
    • F. Hoffmann-La Roche
    • Ferring BV
    • Ipsen
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd

第7章 市場機会および将来動向

目次
Product Code: 61711

The Human Growth Hormone Market registered a market size of USD 4,632.54 million in 2020 and is expected to reach USD 7,567.74 million by 2026, registering a CAGR of 8.61 % during the forecast period.

According to a research article by Mohamed Hamdy Elkarow et al., published in Frontiers in Endocrinology Journal November 2020, patients with decreased growth hormone secretion constitute a risk factor for COVID-19 severity, which requires attention towards preventive measures in susceptible individuals.

In addition, patients with Prader-Willi syndrome should take extra precautions to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not show typical symptoms such as a high temperature and they may also experience a higher-than-normal pain threshold which may delay in the diagnosis of COVID-19.

The major factors driving the market growth include development of recombinant human growth hormone drugs, rise in pituitary dysfunction cases and rising off-label use of human growth hormone.

In humans the growth hormone deficiency is caused when the pituitary gland does not synthesize enough concentration of human growth hormone. This deficiency is treated by administering recombinant human growth hormone by subcutaneous injection. Various genetic disorders such as Prader-Willi syndrome and Turner syndrome, may also cause growth hormone deficiency leading to delayed puberty and shorter-than-average height.

Turner syndrome also known as Congenital ovarian hypoplasia syndrome, occurs when the X chromosome is partially or completely missing in females. According to a research article by Xiaoxiao Cui et al., published in Intractable & Rare Diseases Research Journal 2018, globally, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 female live births.

The human growth hormone helps to stimulate regeneration, reproduction and growth. Rising use of growth hormone and awareness about the growth hormone which helps in the management of growth hormone deficiency disorderswhich is boosting the market growth.

Furthermore, most companies are investing in R&D for developing a growth hormone that has fewer side effects and will be long-acting hormonal therapy. In addition, rapid developments of new novel recombinant human growth hormone is expected to drive the human growth hormone market, over the forecast period.

Key Market Trends

Turner Syndrome Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Turner syndrome is a rare chromosomal disorder that affects females. It is characterized by the partial or complete loss of one of the X chromosomes. The symptoms of Turner syndrome include a wide neck and a low or indistinct hairline, a tendency to develop high blood pressure, minor eye problems, drooping of the eyelids, and an under-active thyroid gland.

Individuals with Turner syndrome are at higher risk for severe illness from the COVID-19 virus. In addition, Turner syndrome patients often present with congenital heart disease, including having a bicuspid aortic valve. Heart disease is an underlying medical condition that can result in severe complications from COVID-19.

According to a research article by Xiaoxiao Cui et al. published in Intractable & Rare Diseases Research 2018, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 female live births. It is highly prevalent in China.

Since Turner syndrome is associated with many complications related to heart, autoimmune disorders, mental health issues, hearing loss, infertility, and pregnancy complications, the demand for treatment involving growth hormones is increasing which is boosting the market growth.

Increasing awareness about early diagnosis and treatment of Turner syndrome by various public and private organizations is expected to boost the market growth. For instance, non-profit organizations such as Turner Syndrome Support Society United Kingdom, Turner Syndrome Society of the United States and Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" in February every year and launched a nationwide campaign to spread awareness about the condition.

Furthermore, increasing research and development in the development of effective therapeutics for Turner syndrome (TS) shows positive impact on market growth. For instance, as per research study published in Intractable & Rare Diseases Research 2018, the next generation of treatment for Turner syndrome (TS) will be based on stem cells and regenerative medicine. Thus, considering above factors it is expected to show significant growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The major factors driving the market growth in the United States include increasing research and development activities, favorable reimbursement policies, established healthcare infrastructure, significant government initiatives, and growing healthcare awareness.

As per Foundation for Prader-Willi Research registry data August 2020, in people with Prader-Willi Syndrome, the COVID-19 showed impact on access to medical care and therapies due to COVID-19-related restrictions in United States. In addition, due to COVID-19 related restrictions showed impact on temporarily access to physical, occupational, speech, and psychological therapies. There was a 60-80% decline in access to Prader-Willi Syndrome related therapies.

According to a research article by Jessica Bohonowych et al., published in Genes Journal 2019, Prader-Willi syndrome (PWS) is a rare genetic disorder with an estimated prevalence of approximately 10,000 to 20,000 living individuals in the United States.

As per the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the United States. Recombinant growth hormone has been widely available for chronic renal insufficiency, growth hormone deficiency (GHD), gestational age or intrauterine growth retardation, Turner's syndrome, Prader-Willi syndrome, and cachexia in the United States.

Furthermore, increasing awareness about growth hormone deficiencies and treatment is expected to boost the market growth. For instance, every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates Children's growth awareness day to spread awareness about the early diagnosis and treatment of growth hormone disorders.

Increasing research and development activities in the development of effective therapeutics resulting in increasing number of pipeline drugs. For instance, in October 2019, Pfizer Inc. and its partner OPKO Health Inc. announced that its Phase III study investigating Somatrogon in pre-pubertal children with human growth hormone met its primary endpoint of non-inferiority to daily somatropin. Thus, owing to above factors it is expected to show growth over the forecast period.

Competitive Landscape

The Human Growth Hormone Market is moderately consolidated, with a few market players controlling a significant market share. Furthermore, there are several active partnerships for the development of more efficacious and long-acting subtypes of human growth hormones. Some of the key market players include AnkeBio Co. Ltd, Eli Lilly and Company, Ferring BV, Novo Nordisk AS, Ipsen S.A., Pfizer Inc, Genentech, Inc (Roche) and Teva Pharmaceutical Industries, Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Development of Recombinant Human Growth Hormone Drugs
    • 4.2.2 Rise in Pituitary Dysfunction Cases
    • 4.2.3 Rising Off-label Use of Human Growth Hormone
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects Associated with Human Growth Hormone
    • 4.3.2 Stringent Regulatory Processes
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Growth Hormone Deficiency
    • 5.1.2 Turner Syndrome
    • 5.1.3 Idiopathic Short Stature
    • 5.1.4 Prader-Willi Syndrome
    • 5.1.5 Other Applications
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital and Retail Pharmacy
    • 5.2.2 Online Pharmacy
    • 5.2.3 Other Distribution Channels
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (By Application and By Distribution Channel)
      • 5.3.1.2 Canada (By Application and By Distribution Channel)
      • 5.3.1.3 Mexico (By Application and By Distribution Channel)
    • 5.3.2 Europe
      • 5.3.2.1 Germany (By Application and By Distribution Channel)
      • 5.3.2.2 United Kingdom (By Application and By Distribution Channel)
      • 5.3.2.3 France (By Application and By Distribution Channel)
      • 5.3.2.4 Italy (By Application and By Distribution Channel)
      • 5.3.2.5 Spain (By Application and By Distribution Channel)
      • 5.3.2.6 Rest of Europe (By Application and By Distribution Channel)
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China (By Application and By Distribution Channel)
      • 5.3.3.2 Japan (By Application and By Distribution Channel)
      • 5.3.3.3 India (By Application and By Distribution Channel)
      • 5.3.3.4 Australia (By Application and By Distribution Channel)
      • 5.3.3.5 South Korea (By Application and By Distribution Channel)
      • 5.3.3.6 Rest of Asia-Pacific (By Application and By Distribution Channel)
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC (By Application and By Distribution Channel)
      • 5.3.4.2 South Africa (By Application and By Distribution Channel)
      • 5.3.4.3 Rest of Middle East and Africa (By Application and By Distribution Channel)
    • 5.3.5 South America
      • 5.3.5.1 Brazil (By Application and By Distribution Channel)
      • 5.3.5.2 Argentina (By Application and By Distribution Channel)
      • 5.3.5.3 Rest of South America (By Application and By Distribution Channel)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AnkeBio Co. Ltd
    • 6.1.2 EMD Serono Inc.
    • 6.1.3 F.Hoffmann-La Roche Ltd
    • 6.1.4 Ferring BV
    • 6.1.5 Ipsen S.A.
    • 6.1.6 Eli Lilly and Company
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 Sandoz International GmbH (Novartis AG)
    • 6.1.11 Strongbridge Biopharma
    • 6.1.12 GeneScience Pharmaceuticals Co. Ltd
    • 6.1.13 Sinobioway Hygene Biomedicine Co., Ltd
    • 6.1.14 Aeterna Zentaris
    • 6.1.15 LG Life Sciences

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.